Ignite Creation Date:
2025-12-24 @ 11:58 PM
Ignite Modification Date:
2026-02-24 @ 4:10 AM
Study NCT ID:
NCT02414958
Status:
COMPLETED
Last Update Posted:
2019-01-03
First Post:
2015-04-08
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)
Sponsor:
Boehringer Ingelheim
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-06-30
Start Date Type:
ACTUAL
Primary Completion Date:
2017-04-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-10-23
Completion Date Type:
ACTUAL
First Submit Date:
2015-04-08
First Submit QC Date:
None
Study First Post Date:
2015-04-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-10-22
Results First Submit QC Date:
None
Results First Post Date:
2018-11-20
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2018-04-11
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2018-12-12
Last Update Post Date:
2019-01-03
Last Update Post Date Type:
ACTUAL